Data Insights

LCB-71 by CStone Pharmaceuticals for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval

LCB-71 is under clinical development by CStone Pharmaceuticals and currently in Phase I for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According...

Likelihood of Approval and Phase Transition Success Rate Model - LCB-71 in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)

Data Insights

LCB-71 by CStone Pharmaceuticals for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

LCB-71 is under clinical development by CStone Pharmaceuticals and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - LCB-71 in Diffuse Large B-Cell Lymphoma

Data Insights

LCB-71 by CStone Pharmaceuticals for Solid Tumor: Likelihood of Approval

LCB-71 is under clinical development by CStone Pharmaceuticals and currently in Phase I for Solid Tumor. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - LCB-71 in Solid Tumor

Data Insights

LCB-71 by CStone Pharmaceuticals for Mantle Cell Lymphoma: Likelihood of Approval

LCB-71 is under clinical development by CStone Pharmaceuticals and currently in Phase I for Mantle Cell Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - LCB-71 in Mantle Cell Lymphoma

Data Insights

LCB-71 by CStone Pharmaceuticals for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval

LCB-71 is under clinical development by CStone Pharmaceuticals and currently in Phase I for B-Cell Non-Hodgkin Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - LCB-71 in B-Cell Non-Hodgkin Lymphoma

Data Insights

LCB-71 by CStone Pharmaceuticals for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

LCB-71 is under clinical development by CStone Pharmaceuticals and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to...

Likelihood of Approval and Phase Transition Success Rate Model - LCB-71 in Triple-Negative Breast Cancer (TNBC)

Data Insights

LCB-71 by CStone Pharmaceuticals for Ovarian Cancer: Likelihood of Approval

LCB-71 is under clinical development by CStone Pharmaceuticals and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - LCB-71 in Ovarian Cancer

Data Insights

LCB-71 by CStone Pharmaceuticals for Pancreatic Cancer: Likelihood of Approval

LCB-71 is under clinical development by CStone Pharmaceuticals and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - LCB-71 in Pancreatic Cancer

Data Insights

LCB-71 by CStone Pharmaceuticals for Non-Small Cell Lung Cancer: Likelihood of Approval

LCB-71 is under clinical development by CStone Pharmaceuticals and currently in Phase I for Non-Small Cell Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - LCB-71 in Non-Small Cell Lung Cancer